Biodistribution and tumor infectivity of Semliki Forest virus vectors in mice: Effects of re-administration

Molecular Therapy

Volumn 15, Issue 12, 2007, Pages 2164-2171

  Rodriguez Madoz, Juan R ^a   Prieto, Jesus ^a   Smerdou, Cristian ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; GENDER; GONAD; HEART; IMMUNOCOMPETENCE; INOCULATION; KIDNEY INFECTION; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REINFECTION; RETREATMENT; SEMLIKI FOREST ALPHAVIRUS; SPLEEN; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS PARTICLE;

ANIMALIA; MUS; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 36349020233     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300274     Document Type: Article

References (40)

1. Strauss, JH and Strauss, EG (1994). The alphaviruses: Gene expression, replication, and evolution. Microbiol Rev 58: 491-562.
2. Xiong, C, Levis, R, Shen, P, Schlesinger, S, Rice, CM and Huang, HV (1989). Sindbis virus: An efficient broad host range vector for gene expression in animal cells. Science 243: 1188-1191.
3. Liljestrom, P and Garaff, H (1991). A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 9: 1356-1361.
4. Pushko, P, Parker, M, Ludwig, GV, Davis, NL, Johnston, RE and Smith, JF (1997). Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389-401.
5. Smerdou, C and Liljestrom, P (1999). Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 73: 1092-1098.
6. Glasgow, GM, McGee, MM, Sheahan, BJ and Atkins, GJ (1997). Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol 78: 1559-1563.
7. Glasgow, GM, McGee, MM, Tarbatt, CJ, Mooney, DA, Sheahan, BJ and Atkins, GJ (1998). The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 79: 2405-2410.
8. Lundstrom, K (2003). Semliki Forest virus vectors for large-scale production of recombinant proteins. Methods Mol Med 76: 525-543.
9. Lundstrom, K (2002). Alphavirus-based vaccines. Curr Opin Mol Ther 4: 28-34.
10. Rayner, JO, Dryga, SA and Kamrud, KI (2002). Alphavirus vectors and vaccination. Rev Med Virol 12: 279-296.
11. Berglund, P, Fleeton, MN, Smerdou, C and Liljestrom, P (1999), Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17: 497-507.
12. Chikkanna-Gowda, CP, 5heahan, BJ, Fleeton, MN and Atkins, GJ (2005). Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12: 1253-1263.
13. Rodriguez-Madoz, JR, Prieto, J and Smerdou, C (2005). Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 12: 153-163.
14. Atkins, GJ, Smyth, JW, Fleeton, MN, Galbraith, SE and Sheahan, BJ (2004). Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4: 527-607.
15. Colmenero, P, Chen, M, Castanos-Velez, Liljestrom, P and Jondal, M (2002). Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 98: 554-560.
16. Asselin-Paturel, C, Lassau, N, Guinebretiere, JM, Zhang, J, Gay, F, Bex, F et al. (1999). Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6: 606-615.
17. Yamanaka, R (2004). Alphavirus vectors for cancer gene therapy (review). Int J Oncol 24: 919-923.
18. Vaha-Koskela, MJ, Kallio; JP, Jansson, LC, Heikkila, JE, Zakhartchenko, VA, Kallajoki, MA et al. (2006). Oncolytic capacity of attenuated replicative semliki Forest virus in human melanoma xenografts in severe combined immunoddeficient mice. Cancer Res 66: 7185-7194.
19. Vaha-Koskela, MJ, Tuittila, MT, Nygardas, PT, Nyman, JK, Ehrengruber, MU, Renggli, M et al. (2003). A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 9: 1-15.
20. Helenius, A, Morein, B, Fries, E, Simons, K, Robinson, P, Schirrmacher, V et al. (1978). Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. Proc Natl Acad Sci USA 75: 3846-3850.
21. Oldstone, MB, Tishon, A, Dutko, FJ, Kennedy, SI, Holland, JJ and Lampert PW (1980). Does the major histocompatibility complex serve as a specific receptor for Semliki Forest virus? J Virol 34: 256-265.
22. Wang, KS, Kuhn, RJ, Strauss, EG, Ou, S and Strauss, JH (1992). High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 66: 4992-5001.
23. Tseng, JC, Hurtado, A, Yee, H, Levin, B, Boivin, C, Benet, M et al. (2004). Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 64: 6684-6692.
24. Tseng, JC, Levin, B, Hurtado, A, Yee, H, Perez de Castro, I, Jimenez, M et al. (2004). Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22: 70-77.
25. Colmenero, P, Berglund, P, Kambayashl, T, Biberfeld, P, Liljestrom, P and Jondal, M (2001). Recombinant Semliki Forest Virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther 8: 1307-1314.
26. Morris-Downes, MM, Phenix, KV, Smyth, J, Sheahan, BJ, Lileqvist, S, Mooney, DA et al. (2001). Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19: 1978-1988.
27. Fazakerley, JK, Cotterill, CL, Lee, G and Graham, A (2006). Virus tropism, distribution, persistence and pathology in the corpus callosum of the Semliki Forest virus-infected mouse brain: A novel system to study virus-oligodendrocyte interactions. Neuropathol Appl Neurobiol 32: 397-409.
28. Lundstrom, K, Schweitzer, C, Rotmann, D, Hermann, D, Schneider, EM and Ehrengruber, MU (2001). Semliki Forest virus vectors: Efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett 504: 99-103.
29. Cook, SH and Griffin, DE (2003). Luciferase imaging of a neurotropic viral infection in intact animals. J Virol 77: 5333-5338.
30. Davidoff, AM, Ng, CY, Zhou, J, Spence, Y and Nathwani, AC (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102: 480-488.
31. Wells, DJ and Goldspink, G (1992). Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscle. FEBS Lett 306: 203-205.
32. Maatta, AM, Liimatainen, T, Wahlfors, T, Wirth, T, Vaha-Koskela, M, Jansson, L et al. (2007). Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 121: 863-870.
33. Ohno, K, Sawai, K, Iijima, Y, Levin, B and Meruelo, D (1997). Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 15: 763-767.
34. Iijima, Y, Ohno, K, Ikeda, H, Sawai, K, Levin, B and Meruelo, D (1999). Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Int J Cancer 80: 110-118.
35. Tirapu, I, Arina, A, Mazzolini, G, Duarte, M, Alfaro, C, Feijoo, E et al. (2004). Improving efficacy of intedeukin-1 2-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 110: 51-60.
36. Hallden, G, Hill, R, Wang, Y, Anand, A, Liu, TC, Lemoine, NR et al. (2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 8: 412-424.
37. Hillman, GG, Slos, P, Wang, Y, Wright JL, Layer, A, De Meyer, M et al. (2004). Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther 11 61-72.
38. Liljestrom, P and Garoff, H (1994). Expession of proteins using Semliki Forest virus vectors. In: Ausubel, FM, Brent, P, Kingston, RE, Moore, DD, Seidman, JD, Smith, JA et al. (eds.). Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley Interscience: New York. pp. 16.20.11-16.20.16.
39. Fleeten, MN, Sheahan, BJ, Gould, EA, Atkins, GJ and Liljestrom, P (1999). Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 80: 1189-1198.
40. Salminen, A, Wahlberg, JM, Lobigs, M, Liljestrom, P and Garoff, H (1992). Membrane fusion process of Semliki Forest virus. II: cleavage-dependent reorganization of the spike protein complex controls virus entry. J Cell Biol 116: 349-357.